Hepatic tumors with hyperglucagonemia response to treatment with human lymphoblastoid interferon
β Scribed by Robert A. Sheehan-Dare; Adrian V. Simmons; John A. Cotterill; Phillip G. Janke
- Publisher
- John Wiley and Sons
- Year
- 1988
- Tongue
- English
- Weight
- 665 KB
- Volume
- 62
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract A pilot study was designed to determine the tolerance and effectiveness of natural or recombinant gamma interferon in patients with chronic hepatitis B. Sixteen patients received 0.5 to 3.0 million units (MU) per day of gamma interferon (IFNβΞ³) for 7 days. Nineteen chronic hepatitis B p
Hepatitis C virus (HCV) carriers with normal aminotransferase levels often show histological chronic hepatitis. This study was undertaken to determine the effect of interferon (IFN) in such patients. Nineteen HCV carriers with normal aminotransferase activities and chronic hepatitis were randomized
## Abstract One hundred fiftyβfive chronic hepatitis C patients were assigned at random to receive natural lymphoblastoid interferon (IFN)Ξ±βn1, s.c., for 13 months in one of three treatment regimens: initial daily induction with 10 million units (MU) followed (group 1, nβ=β50) or not (group 2, nβ=β
## Abstract The response marker for interferon has not been investigated fully for hepatitis B viruses (HBVs) in the Philippines where novel subtypes B5 and C5 were recognized recently. The prediction parameters for interferon treatment were assessed, with emphasis on the mutation patterns in the b